A HNF4a-caGR fusion transcription factor as potential treatment for inflammatory liver diseases and liver cancer

Background:

Liver diseases and liver cancer often involve impaired function of hepatocyte nuclear factor 4α (HNF4α) and glucocorticoid receptor (GR) pathways, leading to disrupted hepatocyte differentiation, metabolism, and anti-inflammatory responses. Traditional treatments struggle to effectively target these transcriptional deficiencies due to resistance mechanisms and widespread systemic side effects, creating a critical need for a targeted therapeutic approach that can overcome these challenges.

Technology Overview:

The HNF4α-caGR fusion transcription factor combines the functional domains of hepatocyte nuclear factor 4α (HNF4α) and a constitutively active glucocorticoid receptor (caGR) into a single engineered protein. This fusion enables cooperative DNA binding and transcriptional activation at specific gene sites that are essential for liver cell differentiation, metabolic regulation, and anti-inflammatory processes. By enforcing this cooperative engagement, the fusion factor effectively bypasses the usual transcriptional resistance seen in diseased liver cells. Unlike conventional glucocorticoid therapies that trigger widespread gene activation and significant systemic toxicity, this fusion selectively targets genes critical to liver health, minimizing off-target effects. The modular design of the fusion factor allows further modifications to optimize its functional properties, such as enhancing DNA-binding specificity or improving delivery to liver cells. This targeted approach not only restores key pathways simultaneously but also reduces harmful side effects, offering a novel geometry-driven strategy for transcriptional therapy.

Advantages:

•    Dual Pathway Restoration: Simultaneously reactivates both HNF4α and GR pathways critical to liver cell function.
•    Selective Activation: Precisely targets specific genes, reducing unwanted effects on non-target tissues.
•    Overcoming Resistance: Effective for treating conditions that are resistant to traditional glucocorticoid treatments.
•    Reduced Toxicity: Liver-focused delivery limits systemic exposure and associated adverse effects.
•    Modular Design: Allows customization to improve efficacy, specificity, and delivery options.
•    Broad Applicability: Useful across a range of liver-related diseases and other inflammatory or systemic conditions.

Applications:

•    Treatment of inflammatory liver diseases, including hepatitis and fibrosis.
•    Therapeutic approach for liver cancers by restoring normal transcriptional regulation.
•    Potential use in managing systemic inflammatory conditions such as sepsis.
•    Gene regulation therapies aimed at correcting transcriptional dysregulation in various diseases.

Intellectual Property Summary: Patent pending

Stage of Development: Inquire for stage of development

Licensing Status: This technology is available for licensing.

About the Research Foundation for the State University of New York:

As the nation's largest research foundation supporting the nation's largest public university system, The Research Foundation for SUNY powers research and innovation to address today's most pressing problems and shape a better future for generations to come. The Research Foundations supports SUNY researchers leading the way globally in AI for the public good, quantum technologies, next-generation semiconductors, biotech and medicine, energy and climate solutions, and more. The Research Foundation for SUNY is a private, nonprofit educational corporation that is tax-exempt under Internal Revenue Code (IRC) Section 501(c)(3). To learn more, please visit us online at rfsuny.org.

About the State University of New York

The State University of New York is the largest comprehensive system of higher education in the United States, and more than 95 percent of all New Yorkers live within 30 miles of any one of SUNY’s 64 colleges and universities. Across the system, SUNY has four academic health centers, five hospitals, four medical schools, two dental schools, a law school, the country’s oldest school of maritime, the state's only college of optometry, 12 Educational Opportunity Centers, over 30 ATTAIN digital literacy labs, and manages one US Department of Energy National Laboratory. In total, SUNY serves about 1.7 million students across its portfolio of credit- and non-credit-bearing courses and programs, continuing education, and community outreach programs. SUNY oversees nearly a quarter of academic research in New York. Research expenditures system-wide are nearly $1.5 billion in fiscal year 2025, including significant contributions from students and faculty. There are more than three million SUNY alumni worldwide, and annually one in three New Yorkers who earn a college degree is a SUNY alum. To learn more about how SUNY creates opportunities, visit suny.edu.